AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

South Korea's drug safety ministry said on Wednesday it granted final approval for a shipment of 1.57 million doses of ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

ASTRAZENECA delivered better-than-expected third quarter earnings and retained its full-year forecasts on Thursday, with strong sales of its blockbuster cancer and cardiovascular drugs.

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...